Latest News
& Press Releases

Atomwise inked a strategic research-and-development deal with Sanofi to use the AtomNet platform to identify and research up to five drug targets.

The FDA expects to foster innovation and competition among manufacturers, which would lower the prices of hearing aids without compromising their quality.

Kate Hermans has taken over the reins of Ambrx as interim CEO following the abrupt departure of Feng Tian.

ScribeEMR, a leading provider of real-time remote medical scribe services, announces that it has surpassed its goal to provide remote scribe services on more than 80 EMR platforms, including the top three hospital EMRs and the top five EMRs used by outpatient practices.

Blueprint Medicines’ Ayvakit is headed to the FDA for a new indication after the drug hit the mark in Part 2 of the PIONEER trial for non-advanced systemic mastocytosis.

I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.

All other ongoing and pending studies of Sanofi’s amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.

BioSpace spoke with industry executives and investors about the current economic situation in the biotech industry and sourced tips on how leaders can weather the downturn.

The Bill & Melinda Gates Foundation inked a memorandum of understanding with South Korea’s foreign and health ministries to expand their partnerships revolving around public health.

Researchers found promising connections between the Neuregulin 4 (NRG4) endocrine factor protein and the suppression of specific liver diseases, including NASH.

Novavax seeks EUA for COVID-19 Booster, a 100-year-old TB vaccine may protect against the disease and public health officials struggle with fall planning.

Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead is answering that challenge with Trodelvy.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments